Your browser doesn't support javascript.
loading
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Domchek, Susan M; Postel-Vinay, Sophie; Im, Seock-Ah; Park, Yeon Hee; Delord, Jean-Pierre; Italiano, Antoine; Alexandre, Jerome; You, Benoit; Bastian, Sara; Krebs, Matthew G; Wang, Ding; Waqar, Saiama N; Lanasa, Mark; Rhee, Joon; Gao, Haiyan; Rocher-Ros, Vidalba; Jones, Emma V; Gulati, Sakshi; Coenen-Stass, Anna; Kozarewa, Iwanka; Lai, Zhongwu; Angell, Helen K; Opincar, Laura; Herbolsheimer, Pia; Kaufman, Bella.
Afiliação
  • Domchek SM; Basser Center for BRCA, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: susan.domchek@pennmedicine.upenn.edu.
  • Postel-Vinay S; ATIP -Avenir group, Inserm Unit U981, Villejuif, France; Faculté de Médicine, Le Kremlin Bicêtre, Université Paris Saclay, Université Paris-Sud, Villejuif, France; Department of Drug Development, Gustave Roussy, Villejuif, France.
  • Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of South Korea.
  • Park YH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of South Korea.
  • Delord JP; Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Italiano A; Institut Bergonié, Bordeaux, France.
  • Alexandre J; Hôpital Cochin, Paris, France.
  • You B; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon, Centre d'Investigation de Therapeutiques en Oncologie et H ematologie de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France; Faculté de Médecine Lyon-Sud, Univ Lyon, Université Claude Bernard Lyon 1, EMR UCBL/HCL 3738, Lyon, France
  • Bastian S; Kantonsspital Graubuenden, Chur, Switzerland.
  • Krebs MG; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK; Manchester Academic Health Science Centre, Manchester, UK.
  • Wang D; Henry Ford Medical Center, Detroit, MI, USA.
  • Waqar SN; Washington University School of Medicine, Saint Louis, MO, USA.
  • Lanasa M; AstraZeneca, Gaithersburg, MD, USA.
  • Rhee J; AstraZeneca, Gaithersburg, MD, USA.
  • Gao H; AstraZeneca, Cambridge, UK.
  • Rocher-Ros V; AstraZeneca, Cambridge, UK.
  • Jones EV; AstraZeneca, Cambridge, UK.
  • Gulati S; AstraZeneca, Cambridge, UK.
  • Coenen-Stass A; AstraZeneca, Cambridge, UK.
  • Kozarewa I; AstraZeneca, Cambridge, UK.
  • Lai Z; AstraZeneca, Gaithersburg, MD, USA.
  • Angell HK; AstraZeneca, Cambridge, UK.
  • Opincar L; AstraZeneca, Gaithersburg, MD, USA.
  • Herbolsheimer P; AstraZeneca, Gaithersburg, MD, USA.
  • Kaufman B; Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Lancet Oncol ; 21(9): 1155-1164, 2020 09.
Article em En | MEDLINE | ID: mdl-32771088
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Neoplasias da Mama / Proteína BRCA1 / Proteína BRCA2 / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Neoplasias da Mama / Proteína BRCA1 / Proteína BRCA2 / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article